Males with PLS3 pathogenic variants experience severe osteoporosis and fracture at a young age (MIM#300,910), while in females with heterozygous pathogenic variants clinical presentation can vary in severity [17, 18]. This evidence concerns the gene PLS3 and osteoporosis.